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Oct4/Pou91Sox1, Sox2 and Sox3, the three members of the SoxB1 subgroup of transcription factors, have similar
sequences, expression patterns and overexpression phenotypes. Thus, it has been suggested that they have
redundant roles in the maintenance of neural stem cells in development. However, the long-term effect of
overexpression or their function in combination with their putative co-factor Oct4 has not been tested. Here,
we show that overexpression of sox1, sox2, sox3 or oct91, the Xenopus homologue of Oct4, results in the same
phenotype: an expanded neural plate at the expense of epidermis and delayed neurogenesis. However, each
of these proteins induced a unique proﬁle of neural markers and the combination of Oct91 with each SoxB1
protein had different effects, as did continuous misexpression of the proteins. Overexpression studies indicate
that Oct91 preferentially cooperates with Sox2 to maintain neural progenitor marker expression, while
knockdown of Oct91 inhibits neural induction driven by either Sox2 or Sox3. Continuous expression of Sox1
and Sox2 in transgenic embryos represses neuron differentiation and inhibits anterior development while
increasing cell proliferation. Constitutively active Sox3, however, leads to increased apoptosis suggesting that
it functions as a tumor suppressor. While the SoxB1s have overlapping functions, they are not strictly
redundant as they induce different sets of genes and are likely to partner with different proteins to maintain
progenitor identity.r), jj323@georgetown.edu
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Neural progenitor identity in vertebrates is regulated in part by the
three members of the SoxB1 subgroup of transcription factors, Sox1,
Sox2 and Sox3 (Bylund et al., 2003; Graham et al., 2003; Pevny et al.,
1998), which maintain proliferation of these multipotent neural
progenitors and prevent their differentiation. Overexpression of
either Sox1, Sox2 or Sox3 expands the progenitor cell population
and inhibits neuronal differentiation in P19 cells (Sox1: Pevny et al.,
1998), the chick neural tube (Sox2 and 3: Bylund et al., 2003; Graham
et al., 2003) and the Xenopus neural plate (Sox2 and 3: Mizuseki et al.,
1998; Rogers et al., 2009). Since the SoxB1 proteins have similar
expression patterns, protein structures and functions, it has been
suggested that they have redundant roles during neural development
(Collignon et al., 1996; Pevny and Rao, 2003). However, there are
critical differences. The most striking being that only Sox1 has been
shown to convert Xenopus ectodermal explants into neuronal tissue
(Nitta et al., 2006), whereas Sox2 and Sox3 are not sufﬁcient to induce
the formation of neurons, but are necessary to maintain a neural
progenitor population (Mizuseki et al., 1998; Rogers et al., 2009).
Knockdown of Sox2 or Sox3 prevents both neural speciﬁcation and
neuronal differentiation in the Xenopus neural plate (Kishi et al.,2000), and reduction of Sox2 or Sox3 function in the chick spinal cord
increases the number of differentiating neural cells at the expense of
proliferating progenitors (Bylund et al., 2003). Furthermore, the
earliest of the SoxB1s to be expressed, Sox3, may function as a
competency factor, as knockdown of Sox3 prevents Noggin-mediated
induction of neural tissue in Xenopus ectodermal explants (Rogers
et al., 2009).
The SoxB1 proteins are expressed in distinct spatial and temporal
domains during gastrulation, further indicating that each has a unique
role during neural induction. In ﬁsh, chick, and frog, sox3 is expressed
throughout the ectoderm prior to neural induction, and is then
restricted to the neuroectoderm during gastrula stages (Koyano et al.,
1997; Okuda et al., 2006; Penzel et al., 1997; Rex et al., 1997; Rogers et
al., 2008). In contrast, sox2 expression is initiated in early gastrula
embryos and expressed only in the neuroectoderm (Mizuseki et al.,
1998; Nitta et al., 2006; Okuda et al., 2006; Rex et al., 1997; Wood and
Episkopou, 1999), while sox1 is not expressed until the end of
gastrulation in the anterior neuroectoderm (Nitta et al., 2006; Rex et
al., 1997; Wood and Episkopou, 1999).
SoxB1 proteins are important regulators of neural development
but their distinct functions have been difﬁcult to resolve. This is in part
due to their ability to compensate for each other's loss such that in the
loss-of-functionmutants, early neural development appears relatively
normal with only minor consequences to brain structure and function
evident in later stages. This compensation appears to occur in vivo as
evidenced by the up-regulation of sox2 and sox3 expression in
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of sox3 in sox2 conditional knockout mice (Miyagi et al., 2008). Rescue
experiments support the idea that their compensatory ability allows
for only minor defects in loss-of-functions mutants. For example,
addition of Sox1 rescues a decrease in cell proliferation in the chick
spinal cord caused by Sox2 inhibition (Graham et al., 2003).
Conversely, Sox2 compensates for the loss of Sox1 in telencephalic
neurons (Ekonomou et al., 2005). Even though the SoxB1s can
compensate for each other's loss such that early development is
relatively normal, they have distinct roles later in development. Sox3-
null mice have craniofacial defects and paralysis due to a neural crest
migration defect (Rizzoti et al., 2004; Rizzoti and Lovell-Badge, 2007),
whereas Sox1-null mice suffer from epilepsy, have small eyes and
severe neuronal deﬁcits in the forebrain (Malas et al., 2003). A neural-
speciﬁc conditional Sox2 knockout was used to study Sox2's role in
neural development since Sox2-null mice do not survive past
implantation (Episkopou, 2005), and these mice have more severe
phenotypes than the Sox1- or Sox3-null mice (Miyagi et al., 2008).
The embryos have enlarged lateral ventricles and prenatal mortality
(Miyagi et al., 2008).
The loss of any single SoxB1 in non-mammalian vertebrates also
resulted in minor phenotypes, which reinforced the idea that the
SoxB1s are redundant. Sox3 knockdown in zebraﬁsh reduced the size
and disrupted the organization of the neural tube (Dee et al., 2008)
and Sox3 knockdown in Xenopus did not result in an obvious
phenotype but did inhibit Noggin's induction of neural tissue in
ectodermal explants (Rogers et al., 2009). Altogether, the current data
indicate that the ability of SoxB1 proteins to maintain neural
progenitors is redundant, but that they ultimately have unique roles
in different tissues within the brain.
There is increasing evidence that the Sox family of proteins require
partner proteins or co-factors to regulate their target genes (Pevny
and Lovell-Badge, 1997; Wegner, 1999; Wilson and Koopman,
2002). However, only a few partner proteins have been identiﬁed
and these are primarily members of the Pou family of transcription
factors (Kuhlbrodt et al., 1998; Ma et al., 2000; Tanaka et al., 2004).
The best-studied interaction is that between Sox2 and the PouV
transcription factor, Oct3/4. The high level of interest in these two
proteins is in part due to their role in ES self renewal and in
reprogramming differentiated cells into induced pluripotent stem
(iPS) cells (Ambrosetti et al., 1997; Avilion et al., 2003; Babaie et al.,
2007; Kiskinis and Eggan, 2010; Takahashi and Yamanaka, 2006; Yuan
et al., 1995). Both proteins are required for stem cell maintenance. In
the absence of Oct4, sox2 is not expressed in ES cells and they
differentiate into extraembryonic or trophectoderm tissue (Feldman
et al., 1995; Nichols et al., 1998; Yuan et al., 1995). Proper levels of
Sox2 are required for stem cell maintenance as both increased and
decreased levels of Sox2 cue differentiation (Chew et al., 2005; Kopp
et al., 2008) suggesting that high levels of Sox2 interfere with the
formation or function of Sox2:Oct4 complexes and low levels of Sox2
result in too few complexes. In support of this, overexpression of Sox2
in ES cells, embryonic carcinoma cells, and the developing eye leads to
a downregulation of Sox2:Oct4 target genes such as Nanog and FGF4
and decreased proliferation and premature differentiation (Boer et al.,
2007; Kopp et al., 2008; Lin et al., 2009). These data indicate that
expression of Sox2 and its target genes requires Oct4, and that the
Sox2 overexpression phenotypes without the addition of Oct4 are
potentially due to the disruption of the Sox2/Oct4 complex.
Xenopus has the unique characteristic of having three Pou5f1
genes: Oct25, Oct60 and Oct91/Pou91 (Ryan and Rosenfeld, 1997). Of
these three, Oct91 is most effective at rescuing an Oct4-depleted
mouse ES cell line (Morrison and Brickman, 2006) and thus is the
likely Oct4 homologue and Sox2 partner. However, even though Oct4
is not expressed in the developing CNS of mammals, the expression
pattern and loss-of-function experiments indicate that Oct91 plays a
role in neural development in Xenopus. Oct91 is expressed throughoutthe ectoderm in mid-blastulae, restricted to the neural plate during
gastrulation when neural tissue is induced and remains in the neural
tube at the end of neurulation (Morrison and Brickman, 2006).
Knockdown of Oct91 in Xenopus inhibits neural induction as indicated
by the repression of sox2 and zicr1 expression (Snir et al., 2006).
Therefore, Oct91 is expressed at the right time and place to interact
with the SoxB1 proteins in Xenopus neural development.
In this report, we have sought: (1) to delineate the overlapping but
distinct roles for each SoxB1 protein in neural progenitor formation or
maintenance by comparing the target gene expression proﬁle; (2) to
determine their level of cooperation with Oct91, and (3) to examine
the consequences of constitutively-active SoxB1 proteins. Here we
show, through overexpression studies in ectodermal explants, that
Sox1 Sox2 and Sox3 are sufﬁcient for neural induction and initiation of
neurogenesis as evidenced by the induction of neural markers.
However, their expression is insufﬁcient to form neurons. We also
show that Sox2 cooperateswith Oct91 tomaintain a neural progenitor
identity, whereas high levels of Sox1 and Sox3 counteract high levels
of Oct91 in ectodermal explants. Additionally, knockdown of Oct91
depresses the neural inductive properties of both Sox2 and Sox3.
Continuous expression of Sox1 and Sox2 in transgenic embryos
represses neuron differentiation and anterior development while
increasing cell proliferation, whereas constitutively active Sox3 leads
to increased apoptosis. Hence, we provide evidence that all SoxB1
proteins override BMP signaling and induce neural markers, that the
synergy previously seen in mammals between Sox2 and Oct4 is
conserved in frogs, and that the SoxB1 proteins are not simply
redundant but rather display unique functions that warrant further
investigation.
Methods
Embryo culturing and manipulations
Xenopus laevis embryos were obtained using standard methods
(Sive et al., 2000) and staged according to Nieuwkoop and Faber
(Nieuwkoop and Faber, 1994). Ectodermal explants were isolated
from stage 8–9 embryos and cultured in 75% Normal Amphibian
Medium (Slack and Forman, 1980). Explants were collected when
uninjected sibling embryos reached stage 12 or 22.
Plasmid construction
The bicistronic TMmCherry:2A:NLSeGFP vector (from M. Parsons)
was cloned into pEF6/V5-HIS TOPO TA Expression Plasmid (Invitro-
gen). To replace mCherry with the soxB1 genes, the BamHI site
upstream of 2A was mutated to an EcoRI site via site-directed
mutagenesis with the following primer sequence: forward 5′-AGCTG-
TACAAGCAATTCGGAGCCACG-3′ (mutatednucleotides areunderlined).
Following mutagenesis, mCherry was removed by double digestion
with SpeI and EcoRI. SoxB1s were inserted by PCR ampliﬁcation that
added SpeI to 5′ and EcoRI to 3′. Sox1 was ampliﬁed using primers
forward 5′-GGACTAGTTGAATGTACAGCATGATGATGGA-3′ and reverse
5′-CGGAATTCGATGTGTGTCAGTGGCATGGT-3′. Sox2 was ampliﬁed
using primers forward 5′-GGACTAGTATGTACAGCATGATGGAGACCG-
3′ and reverse 5′-CGGAATTCCATGTGCGACAGAGGCAGCGT-3′. Sox3was
ampliﬁed using primers forward 5′-GGACTAGTATGTATAGCATGTTG-
GACACC-3′ and reverse 5′-CGGAATTCTTATATGTGAGTGAGCGGTA-3′.
SoxB1s were cloned in frame starting at the ATG.
Primary Xenopus cell cultures and transfection
Primary cultures of Xenopus ﬁbroblast cells were derived and
cultured from stage 30 embryos using standard procedures (Goswami
et al., 2003; Kanamori and Brown, 1993; Rafferty, 1969). The eyes, gut,
skin and tail of the embryos were removed and the remaining tissue
Fig. 1. Oct91 and Sox1 expand the neural tube and repress epidermal formation
similarly to Sox2 and 3. (A–D) Bright ﬁeld and ﬂuorescent microscopy of stage 17
embryos injected with Sox1, Sox2, Sox3 or Oct91 and GFP mRNA into one cell of a two-
cell stage embryo. (E–H)WISH for epi-k expression in embryos injected with soxB1 and
LacZ, or oct91 and GFPmRNA. Asterisk in E marks the injected side. The injected sides of
Sox1 (180/190), Sox2 (135/152), Sox3 (81/81) and Oct91 (49/53) have repressed epi-k
expression compared to their uninjected side. All views are dorsal with anterior to the
left. Brackets in A–D compare the relative width of the neural tube of the uninjected
(top) to the injected side (bottom).
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with 70% trypsin solution (Gibco), and cultured in 70% Leibovitz's
L-15 (Invitrogen). Transfectionwith FugeneHD(Roche)wasperformed
following themanufacturer's directions and optimized to a ratio of 11 μl
Fugene HD to 2 μg DNA.
mRNA and morpholino microinjections
Synthetic cappedmRNAsweremade by in vitro transcription using
mMessage mMachine kits (Ambion). Amounts injected for analysis in
embryos were as follows: 400 pg of sox3-GR (Kishi et al., 2000),
500 pg of sox1 (gift from T. Grammer and R. Harland), 500 pg of sox2
(Mizuseki et al., 1998), 500 pg of sox3 (Hardcastle and Papalopulu,
2000), 500 or 1000 pg of oct91 (Frank and Harland, 1992), 600 pg of
each bicistronic soxB1, 300 pg of eGFP (Clonetech), and 300 pg of lacZ.
Amounts injected for explant analysis were as follows: 15 ng Oct91
morpholino (Snir et al., 2006), 25 pg noggin (Knecht et al., 1995),
200 pg sox3-VP16 (Zhang et al., 2003), 500 pg for low dose, 800 pg for
high dose of soxB1 genes, 1000 pg for high dose of oct91, and for co-
injections each are injected at the low dose. All injections of soxB1 and
oct91 are done at either a high dose or a low dose but only the data
from the high dose injections are shown. The co-injections are done
with each mRNA at the low dose for a sum equivalent to the single
high dose.
Generation of transgenic embryos
Transgenic embryos were generated as originally described (Kroll
and Amaya, 1996) with the following modiﬁcations: 250 ng of
linearized DNA, 5 μl sperm diluent buffer (SDB) and 3.5×104 nuclei/
ml were incubated with 5 μl of metaphase oocyte cytoplasm extract
until nuclei decondense (approximately 8 min) (for comprehensive
methods see Ishibashi et al., 2008). This was diluted in SDB to 70
nuclei/μl with 520 μl of SDB and kept at 15 °C until injected into
oocytes at a ﬂow rate of 0.6 μl/min over approximately 2 s.
Whole-mount in situ hybridization and β-galactosidase assay
Whole-mount in situ hybridization (WISH) was performed as
described (Harland, 1991; Hemmati-Brivanlou et al., 1990) with the
following modiﬁcations: proteinase K, paraformaldehyde and acetic
anhydride treatmentswere not done. For lineage tracing,β-galactosidase
activity was visualized with X-gal (Research Organics). For in situ
riboprobes, we used dioxygenin-labeled n-tubulin (Richter et al., 1988),
epi-keratin (Jonas et al., 1985) and sox2 (Mizuseki et al., 1998).
Reverse transcription PCR
RT-PCR was performed as described (Wilson and Hemmati-
Brivanlou, 1995). Total RNA was extracted from 10 ectodermal
explants and cDNA was generated using random hexamer primers
and reverse transcriptase (Bioline). In Fig. 6, however, RNA was
prepared using RNAqueous Kit (Ambion) with 200 μl of lysis buffer
per reaction. Each experiment was performed a minimum of three
times. See Table S1 for primer list and PCR conditions.
Immunohistochemistry
Immunohistochemistry was performed as described (Kyuno et al.,
2003) with the following modiﬁcations: incubated with primary
notochord anti-Tor70 (1:5) (Bolce et al., 1992) or somite anti-12/101
antibodies (1:500) (Kintner and Brockes, 1984); secondary antibody
peroxidase-conjugated goat, anti-rabbit IgG (1:300 Upstate/Milli-
pore) as described (Brivanlou and Harland, 1989; Dent et al., 1989);
peroxidase visualized with DAB Chromogen tablets (Dako). Prolifer-
ating cells were detected with anti-phospho-Histone H3 (Ser10)antibody (Upstate/Millipore). For visualization, dehydrated embryos
were cleared by using 2:1 dilution of benzyl benzoate to benzyl
alcohol (BB:BA) (Hemmati-Brivanlou et al., 1990).
Terminal transferase assay
Embryos were injected with 25 pg of Sox2:2A:GFP or Sox3:2A:GFP
DNA. Whole mount TUNEL assay was performed after (Hensey and
Gautier, 1998) with the following modiﬁcations: TdT enzyme (NEB)
and BMB blocking agent (Roche) were used. Labeled cells were
visualized by WISH as described.
Results
Overexpression of Oct91 and SoxB1 expands the neural plate at the
expense of epidermis and forms posterior protrusions
We demonstrated previously that overexpression of Sox2 or Sox3
expands the neural plate in Xenopus by increasing cell proliferation,
inhibiting epidermis formation and delaying neurogenesis (Rogers
et al., 2009). To determine if Sox1 and Oct91 have similar effects on
neurogenesis, we injected mRNA coding for each protein into one
blastomere at the two-cell stage with GFP as a lineage tracer, thereby
leaving one half of the embryo as an uninjected control. Like Sox2 and
Sox3, Sox1 and Oct91 expanded the neural tube (Figs. 1A–D) and all
four proteins inhibited epidermal formation as marked by decreased
epi-keratin (epi-k) expression in late neurula embryos (Figs. 1E–H)
(Rogers et al., 2009). Furthermore, Oct91, Sox1 and Sox3 repressed
epi-k in lateral and ventral tissues discontinuous from the expanded
neural tube (data not shown).
Since ES cell progenitor maintenance is dependent on the cooper-
ation of Sox2 and Oct4 (Tomioka et al., 2002) and the speciﬁcity of Sox
protein function is dependent on co-regulators (Chew et al., 2005), we
tested the effect of overexpression of SoxB1 proteins in combination
withOct91. Previously,wedemonstrated that overexpressionof Sox2or
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is repressed at stage 14 and later rebounds from this repression likely
due to degradation of the injected mRNA (Rogers et al., 2009). Here we
show that in fact, n-tub expression rebounds from inhibition by Sox1,
Sox2 and Sox3 by stages 15–16, but is still repressed by Oct91 at this
stage (Fig. 2A compared to B–D) but rebounds by stage 23 (Figs. 2E–H).
At stages 15 and 23, embryos co-injected with oct91 and soxB1 mRNA
phenocopied those injected with Oct91 alone; n-tub was inhibited at
stage 15 and expanded at stage 23 (Figs. 2A, E compared to M–R).
However, by stage 30 the embryos co-injected with SoxB1 and Oct91
formed posterior protrusions not found in the single-injected SoxB1 or
Oct91 injected embryos (Figs. 2I–L compared to T–V). The protrusions
contain neural tissue, as demonstrated by n-tub expression but did not
contain muscle or notochord tissue and consequently are not secondary
axes (Supplemental Fig. 1). To rule out the possibility that doubling the
total amountof injectedmRNAwas thecauseof theposteriorprotrusions,
we injected two times the amount of oct91 mRNA (Fig. 2S). A higher
concentration of Oct91 did not recapitulate the posterior protrusions,
indicating that Oct91 synergized with SoxB1 to form posterior protru-
sions. These data along with loss-of function studies which demonstrate
that Sox2, Sox3 and Oct91 are required for the expression of neural
progenitor markers (Kishi et al., 2000; Rogers et al., 2009; Snir et al.,
2006), indicate thatOct91 cooperateswith the SoxB1s to expand a neural
progenitor pool that eventually differentiates into a mass of neurons.
SoxB1s and Oct91 are sufﬁcient to induce neural tissue in naïve ectoderm
Previous studies concluded that Sox2 was insufﬁcient to induce
neural tissue in ectodermal explants excised from blastula embryos
but when combined with FGF did induce neurons in explants excised
from gastrula embryos (Mizuseki et al., 1998). One possibility is that
the SoxB1 proteins require a partner protein to neuralize ectoderm. To
address this possibility, ectodermal explants were isolated fromFig. 2.Oct91 and the SoxB1s synergize to induce posterior protrusions. (A–L)WISH for n-tub
sox1, sox2, or sox3mRNA. Arrowhead in B marks laterally displaced neurons. Ectopic neuron
injected in one ventral blastomere of a four-cell embryo with oct91 alone or in combination w
M–R the injected side is the bottom half of the embryo. In I–L and S–V only the injected sidembryos injected with mRNA coding for GFP and either each soxB1
alone (800 pg) or sox2 (400 pg) plus sox3 (400 pg) to determine if
they cooperate with each other, or the dominant activator form sox3-
VP16which does not require a partner protein for strong activation of
transcription (Emami and Carey, 1992; Wu et al., 1994). These were
cultured until late gastrula (Fig. 3) and early tailbud (Fig. 4) and
assayed by RT-PCR.
Sox2 and Sox3 overexpression induced different sets of markers in
ectodermal explants. In gastrula stage explants, Sox2 induced
expression of sox1, slug and the neural progenitor marker musashi
(msi1, also known as neural related protein-1 or nrp-1) (Fig. 3B). Sox3
induced these and other markers including the early neural markers
geminin (gem) and zicR1, the anterior neural marker eomesodermin
(eomes, also known as Tbr2), and the proneural gene neurogeninr-1
(ngnr-1). Neither induced the neuronal marker n-tub and co-
injections of Sox2 and Sox3 showed an expression proﬁle similar to
that of Sox3 (Figs. 3B, 4A). These data indicate that Sox2 and Sox3 are
sufﬁcient to inhibit epidermis formation and induce different subsets
of early neural genes but are not sufﬁcient to induce the formation of
neurons, as noted by the absence of n-tub expression (Fig. 4A).
We showed previously that in embryos, Sox3 activates sox2
directly (Rogers et al., 2009), however Sox3 is not sufﬁcient to induce
sox2 expression in ectodermal explants (Figs. 3B, 4A). One possibility
is that Sox3 requires a partner protein to induce sox2. In support of
this, Sox3-VP16 is sufﬁcient to induce sox2 and consequent n-tub
expression (Fig. 4A). This suggests that in ectodermal explants, Sox3 is
missing its partner protein and therefore, unable to activate sox2
expression.
A candidate partner protein for the SoxB1 proteins is Oct91, the
Xenopus homologue of Oct4. Oct91 alone is sufﬁcient for neural
induction as marked by NCAM expression in ectodermal explants
(Snir et al., 2006), and we determined that Oct91 also induced gem,
sox3, sox2, sox1, eomes, msi1 and n-tub (Fig. 4B, stage 22 andin embryos injected in one blastomere of the four-cell stage embryo with LacZ and oct91,
s are seen at both stages 23 and 30 in all treatments. (M–V) WISH for n-tub in embryos
ith sox1, sox2 or sox3, and LacZ. Asterisk in top rowmarks the injected side. In A–H and
e is shown.
Fig. 3. Sox3 induces neural gene expression in gastrula-staged ectodermal explants. (A) Diagram of ectodermal explant assay. mRNA is injected into both blastomeres of the two-cell
embryo. GFPwas injected in all treatments as a lineage tracer. Explants are excised at stages 8–9. Cultured explants that are ubiquitous for GFP are collected and processed by RT-PCR.
(B) RT-PCR analysis of stage 12 ectodermal explants that are uninjected (UI) or injected with noggin, sox2 or sox3, sox2 plus sox3. A whole embryo (WE) control is also shown. In the
co-injected caps, the total amount of RNA injected equals that of sox2 or sox3 injected singly. The caps are negative for bra and therefore do not have mesoderm contamination. (C)
Diagrams of Sox3 and Sox3-VP16. Twenty amino acids were removed from the C-terminus and replaced with VP16 (diagram adapted from Kamachi et al., 2000).
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embryos has been shown to correspondingly reduce sox2 expression
(Snir et al., 2006). To determine the extent to which Sox2 and Sox3
cooperate with Oct91, we co-injected mRNA coding for either Sox2 or
Sox3 with Oct91. The addition of Sox2 did not alter the induction of
progenitor marker expression by Oct91. In contrast, Sox3 prevented
Oct91 from inducing any neural markers even though epi-k was still
repressed. These data are consistent with the interpretation that Sox2
cooperates with Oct91 to maintain a neural progenitor identity,
whereas Sox3 and Oct91 counteract each other in ectodermal
explants. These results were obtained in both gastrula (Supplemental
Fig. 2) and neurula (Fig. 4) staged caps.
Sox1, expressed at the end of gastrulation later than both sox2 and
sox3, induces the expression of n-tub and the pan-neural marker
NCAM in late stage explants (stage 32) (Nitta et al., 2006). To
determine the effect of Sox1 on early neural marker expression and if
this is altered by the addition of Oct91, ectodermal explants were
isolated from embryos injected with sox1, oct91, or oct91 plus sox1
mRNA. Individually, Sox1 or Oct91 induced expression of theprogenitor markers sox3, sox2 andmsi1 in stage 22 explants; however,
together they activated only sox2 (Fig. 5). In summary, Sox1 and Sox3
both induce a broad proﬁle of progenitor markers while Sox2 induces
a small subset of these. Even though overexpression of Sox2 induces
sox1 expression, the wide array of genes induced by overexpression of
Sox1 is not expressed. Taken together, these results suggest that Sox1
and Sox3 are sufﬁcient for neural induction as marked by expression
of early neural and neural progenitor markers, and all three SoxB1
proteins counteract neuronal differentiation caused by Oct91.
To determine if the SoxB1 proteins require Oct91 to induce neural
marker expression, we knocked down the level of Oct91 proteins by
injection of an Oct91 morpholino (MO) (Snir et al., 2006). Oct91 was
shown previously to be expressed in uninjected ectodermal explants
and embryos at stages 9 through 15 (Frank and Harland, 1992)
making it a candidate partner for the SoxB1 proteins. Here we conﬁrm
this and show that its expression is not maintained in stage 22
explants (Fig. 6A). We also replicated experiments demonstrating
that knockdown of Oct91 with a MO reduced expression of neural
markers such as sox2 and msi1 (Snir et al., 2006) but not sox3, (data
Fig. 4. Sox2, Sox3 and Oct91 induce unique arrays of neural genes in ectodermal explants. (A) RT-PCR analysis of stage 22 whole embryo (WE) or ectodermal explants from embryos
injected with noggin (Nog), sox2 or sox3, sox2 (S2) with sox3 (S3), sox3-VP16 or uninjected (UI). (B) RT-PCR analysis of stage 22 ectodermal explants from embryos injected with
oct91, or low doses of oct91 with sox2 or sox3. GFP was injected in all treatments as a lineage tracer.
434 T.C. Archer et al. / Developmental Biology 350 (2011) 429–440not shown). To test the role of Oct91 in neural tissue formation, we
ﬁrst injected Oct91MOwith the neural inducer noggin, which resulted
in the reduction of all neural markers assayed and an increase in the
expression of epi-k (Fig. 6B). Similarly, the Oct91MO reduced neural
marker expression and prevented the inhibition of epi-k by Sox2 and
Sox3. In contrast, knocking down Oct91 did not alter the Sox1
overexpression phenotype. In summary, Oct91 is expressed in
ectodermal explants during neural induction, and the knockdown of
Oct91 in the presence of the neural inducer noggin or the Sox 2 and 3,
depresses the activation of neural marker gene expression.Fig. 5. Sox1 induces early neural markers and counteracts Oct91-mediated neuron
formation. RT-PCR analysis of stage 22 embryos (WE) or ectodermal explants from
uninjected (UI) embryos, embryos injected with noggin (Nog), sox1 low, oct91 high, or
oct91 plus sox1 (S1). GFP was injected in all treatments as a lineage tracer.Constitutively-active Sox1 and Sox2 retard anterior development and
repress neuronal differentiation in the CNS
Overexpression of each SoxB1 delays n-tub expression (Fig. 2)
(Rogers et al., 2009), but n-tub expression eventually rebounds and is
expanded. This rebound may be due to the depletion and eventual
degradation of the exogenous soxB1 mRNA which causes the
expanded progenitor pool to differentiate. To compare the effect of
a continuous supply of soxB1 mRNA to the transient overexpression
studies, we overexpressed SoxB1 and GFP using a bicistronic construct
with expression driven by the constitutively active EF1α promoter.
Separating the two genes is the 2A oligopeptide from the picornavirus
foot-and-mouth disease virus (FMDV) (de Felipe and Ryan, 2004) that
mediates intraribosomal cleavage such that two proteins are
generated from a single transcript with the 2A peptide maintained
as a tag on the ﬁrst protein (Fig. 7A). To ensure the functionality of the
system in Xenopus, we transfected Xenopus cells and injected embryos
with aﬂuorescent bicistronic expression vector containingmCherrywith
a plasma-membrane localization signal, 2A, and eGFP with a nuclear
localization signal. In transfected cells and embryos, both red ﬂuores-
cence and nuclear green ﬂuorescence were detected (Figs. 7B–H).
mCherrywas replacedbyeachof the soxB1genes (Fig. 7I) and injection of
the bicistronicmRNA into embryos expands the neural plate and inhibits
epidermis formation as shown in Fig. 1.
To determine the effect of constitutive soxB1 gene expression on
embryo development after stage 15, we generated transgenic
embryos using the bicistronic vector shown in Fig. 7I. Our average
transgenic efﬁciency (TE) as determined by in situ hybridization for
GFP is approximately 50% (Rogers et al., 2008). With these constructs,
however, our TE as determined by GFP ﬂuorescence was 8% (50/603
embryos). All of our transgenic embryos had mosaic GFP expression
which indicates either late integration of the plasmid DNA, or that
those embryos with ubiquitous expression failed during develop-
ment. Late integration does not explain the extremely low efﬁciency,
Fig. 6. Oct91 knockdown depresses neural induction by Sox2 and Sox3. (A) RT-PCR analysis of uninjected stage 12.5, 16 and 22 whole embryos (WE) or ectodermal explants. (B) RT-
PCR of ectodermal explants that are either uninjected (UI), or injected with noggin (Nog), sox1, sox2, or sox3 alone or in combination (+) with Oct91 morpholino (MO). The caps are
negative for m act and therefore do not have mesoderm contamination.
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embryos did not survive.
Even though a low percentage of transgenic embryos were
generated, a consistent phenotype was visible in neurula embryos
expressing Sox1:2A:GFP and Sox2:2A:GFP. These embryos developed
slower than the non-GFP-expressing sibling embryos generated from
sperm nuclei injections, and have a smaller cement gland at neurula
stages (data not shown). By tailbud stages, the heads of GFP-positive
embryos fail to develop (16/17 for Sox1; 31/33 for Sox2) (Fig. 8).
To determine the effect of constitutively-active Sox1 and Sox2 on
neuronal differentiation, expression of the neuronal marker n-tubwas
analyzed in Sox1:2A:GFP and Sox2:2A:GFP transgenic embryos
(Figs. 8A–C). There are ectopic neurons in Sox1 and Sox2 transgenic
embryos, and even though these embryos lack n-tub in the region of
the neural tube, they do express n-tub in the brain (10/12). Since
neuron formation is reduced and disorganized in these transgenic
embryos, we next asked if neural progenitors were expanded by
assaying for sox2 expression in the Sox1:2A:GFP transgenic embryos
and for phosphorylated histone 3 (pH3) in the Sox2:2A:GFP
transgenic embryos. Since Sox1 activated expression of both sox2
and sox3 in explants, we expected it to expand expression of sox2 in
the transgenics. However, Sox1:2A:GFP transgenic tailbud embryos
had reduced sox2 expression (Figs. 8D–F). In contrast, Sox2:2A:GFP
transgenic embryos (n=5) had a higher density of pH3 positive cells
(an average of 45 pH3 positive cells per 1.2 mm2 area) compared to
non-GFP sibling embryos generated from sperm nuclei injections
(average of 10 positive cells, n=5) (Figs. 8G–I′). These data indicate
that continuous expression of sox2 led to an increased number of
proliferating progenitors while continuous expression of sox1 led to
ectopic neuron formation. In both cases, anterior neural development
was stunted.Embryos were generated with sperm nuclei transfer using the
Sox3:2A:GFP bicistronic expression vector (n=631), however no
GFP-positive embryos were generated. We knew that the mRNA was
functional because injection of Sox3:2A:GFPmRNA into embryos gave
a predictable Sox3 overexpression phenotype (Fig. 2). Therefore, we
hypothesized that the transgenic cells that were constitutively
expressing Sox3 within the mosaic transgenic embryos did not
survive. To determine if cell death was the cause for a lack of GFP-
positive embryos, we injected 25 pg of Sox3:2A:GFP DNA into the
zygote (Fig. 9). As a control, we also injected 25 pg of Sox2:2A:GFP
DNA. Since we injected linearized plasmid DNA into embryos, we
expected to see mosaic GFP expression in cells near the injection site.
In the Sox2:2A:GFP injected embryos, GFP-positive cells were visible
by late gastrula (data not shown), however we did not see any GFP
expression in individual cells in the Sox3:2A:GFP injected embryos.
Instead, these embryos formed large ﬂuid-ﬁlled cavities that were
positive for GFP ﬂuorescence while still being optically clear under
normal light (data not shown). To determine if these edemas were
caused by cell death, we used terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) to stain for apoptotic cells. At stages
11 and 20, there was a ﬁve-fold increase in the number of Sox3:2A:
GFP embryos that had low (20 TUNEL positive cells per dorsal half) to
high (50 positive cells) levels of apoptosis compared to Sox2:2A:GFP
embryos. Therefore, we conclude that constitutively-active Sox3 led
to increased cell death.
Discussion
The homologous SoxB1 proteins Sox1, Sox2 and Sox3 are
expressed in self-renewing progenitors throughout the development
of the CNS, and gain- and loss-of-function studies in vertebrate model
Fig. 7. A constitutively-active bicistronic vector generates two proteins from a single transcript in Xenopus. (A) A diagram for the bicistronic 2A vector shows that a single transcript
forms two proteins. mCherry (pink) contains a plasma membrane localization signal (PmLS, white) and GFP contains nuclear localization signal (NLS, black). (B–E) Xenopus
embryonic ﬁbroblast cell transfected with the bicistronic system with vector in A. mCherry is in the plasma membrane (C) and GFP in the nucleus (D). (F–H) In vitro transcribed 2A
vector mRNA injected into half of the two-cell stage embryo is visible under a dissecting ﬂuorescent microscope in a neurula stage 17 embryo. (I) Bicistronic constructs used for the
generation of transgenic embryos. Each SoxB1 (purple) is upstream of the 18 amino acid 2A viral sequence (blue) followed by nuclear localizing GFP (green) and poly-A signal
(brown) and expression is controlled by the constitutively-active EFlα promoter (orange). Asterisk marks injected side. Diagram not to scale.
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of neural stemcells (Bylundet al., 2003;Grahamet al., 2003; Pevnyet al.,
1998). Distinct functions have been difﬁcult to tease apart as the SoxB1Fig. 8. Sox1:2A:GFP and Sox2:2A:GFP transgenic embryos have decreased levels of n-tub and
embryo generated from sperm nuclei transfer serves as a staging control. N-tub levels
and (C) Sox2:2A:GFP transgenic embryos. (D–F) WISH for sox2 in stage 30 transgenic Sox1
(G–I) Immunohistochemistry for phosphorylated histone H3 immunohistochemistry in
Hatched box indicates magniﬁed view. (G′–I′) pH3 positive cells have been counted in thproteins compensate for each other's loss such that mutants have mild
phenotypes indicating that the SoxB1 proteins are functionally
redundant (Ekonomou et al., 2005; Graham et al., 2003; Kan et al.,Sox2:2A:GFP have increased proliferation. (A–C) WISH for n-tub. (A) A stage 30 sibling
are reduced in the brain and spinal cord of transgenic embryos. (B) Sox1:2A:GFP
:2A:GFP embryos. Sox2 is not expanded in embryos with small heads or absent heads.
Sox2:2A:GFP transgenic embryos. Embryos are shown at the same magniﬁcation.
e magniﬁed views.
Fig. 9. Sox3:2A:GFP DNA increases cell death. TUNEL staining in (A) uninjected embryos
or those injected with (B, E) Sox2:2A:GFP or (C, F) Sox3:2A:GFP plasmid DNA at the 1
cell stage. (A–C) Stage 11 embryos are animal pole views. (D–F) Stage 20 embryos are
lateral views with anterior to the left. Numbers of embryos with the represented
phenotype are in the lower right corner. (G) Percentages of embryos with relatively
high (more than 50 cells positive), low or no staining.
Fig. 10. Summary of genes induced and cell fates altered by each SoxB1. Overexpression
of each SoxB1 in ectodermal cells inhibits epidermis formation, which is driven by BMP
signaling. Sox3 overexpression leads to the formation of neural progenitors by inducing
expression of gem,msi1, eomes, and sox1. For neuronal differentiation, Sox3 requires the
presence of a co-factor. Sox2 induces expression of sox1 and eomes in explants. Sox1
induces expression of both sox2 and sox3 and ultimately results in differentiation and
the formation of neurons.
437T.C. Archer et al. / Developmental Biology 350 (2011) 429–4402007). The present study demonstrates that although the overexpres-
sionof Sox1, 2 and3 results in similar phenotypes, eachprotein activates
a different proﬁle of genes and has a different effect when constitutively
expressed in explants, transgenic embryos or with a putative partner
protein, Oct91.
Sox1, Sox2 and Sox3 have overlapping and distinct roles in neural
speciﬁcation and differentiation
We demonstrated that overexpression of Sox2 or Sox3 expands
the neural plate, inhibits epidermis formation, and inhibits neurogen-
esis embryos (Rogers et al., 2009) and here we show that over-
expression of Sox1 or Oct91 exerts the same effect. To determine if
these genes use the same mechanism to effect these changes, we
compared the proﬁle of neural genes expressed in ectodermal
explants in response to Oct91 and each SoxB1 protein.We determined
that each induces a unique proﬁle of early neural markers, with Sox1
and Oct91 also inducing expression of the neuronal marker n-tub.
These data indicate that they all override BMP signaling to induce
neural marker expression in explants but only Sox1 and Oct91 induce
the formation of neurons. More importantly, these data indicate that
each SoxB1 protein alters the expression of different target genes
(Fig. 10).
Overexpression studies using transgenic embryos indicated that the
different expression proﬁles induced by each SoxB1 lead to different
phenotypes. Transgenic embryos constitutively expressing Sox1or Sox2
were similar in that they had reduced anterior structures and lacked
neurons in the neural tube but had ectopic neurons. Sox1 inducedmany
ectopic neurons in non-neural tissue whereas Sox2 increased the
population of proliferating cells and induced few ectopic neurons
suggesting that Sox2 ismore effective than Sox1 atmaintaining cells in a
progenitor state. In contrast, we were unable to generate any GFP+
transgenic embryos using Sox3:2A:GFP, and injection of EFlα:Sox3:2A:GFP reporter DNA or high levels of sox3 mRNA into fertilized embryos
caused cell death even though embryos tolerate high levels of Sox1 and
Sox2. Thus, Sox3 appears to have a dynamic role in cell proliferation;
at high levels, Sox3 causes cell death but at lower levels induces
proliferation.
Sox3 can inﬂuence either cell proliferation or death, and like
Geminin, another early neural protein with a similar expression
pattern and function (Kroll et al., 1998), exhibits both oncoprotein
and tumor suppressor functions. There are no published reports of
Sox3 being up-regulated in any neural cancers even though Sox2 has
been identiﬁed in brain tumors (Dong et al., 2004; Wang et al., 2006).
However, sox3 is expressed in lung cancer cells (Güre et al., 2000;
Vural et al., 2005), upregulated in lymphomas (Kim et al., 2003) and
can cause cancerous transformation of chick embryonic ﬁbroblasts
(Xia et al., 2000). Furthermore, it has been suggested that sox3 is
regulated by both oncogene and tumor suppressor proteins since the
human sox3 promoter contains binding sites for the tumor suppressor
USF and the oncogene Sp1 (Kovacevic Grujicic et al., 2005). One
possibility is that the levels of sox3 are tightly regulated and the cells
in the transgenic embryos with high levels of Sox3 apoptose because
the constitutively-active promoter overrides the endogenous regula-
tion mechanism that normally represses Sox3, thereby activating a
tumor-suppressor pathway to cause cell death.
Gain or loss of Oct91, alters the SoxB1 phenotype and gene expression
proﬁle
Since paired homeobox proteins partner with Sox proteins to
regulate gene expression (Wilson and Koopman, 2002) and the only
SoxB1 partner identiﬁed thus far is Oct4 (Yuan et al., 1995), we
examined the effect of the overexpression of SoxB1 and the Xenopus
Oct4 homolog, Oct91. First we show that Oct91 alone, like Sox1,
induces neuron formation in embryos and explants and the
expression of neural progenitor, proneural, and neural crest markers
in ectodermal explants. Howeverwhen co-injectedwith Sox1 or 3, the
majority of these neural markers are not expressed even though
epidermis formation is repressed, indicating that at high levels they
interfere with each other's function in the CNS. In contrast, the
addition of Sox2 does not interfere with or enhance the expression of
progenitor markers by Oct91. However, when injected into embryos,
all three SoxB1 proteins cooperate with Oct91 to induce the formation
of neuron-ﬁlled posterior protrusions. Since this is phenocopied by
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possibility is that Sox3, Oct91 and a third protein (not in explants)
induce expression of Xiro3. In support of this, recently it has been
shown that Xiro3 and Sox3 have similar functions and are in a shared
neural regulatory network (Yan et al., 2009).
Gain-of-function studies in explants indicated that Oct91 coop-
erated with Sox2 but not Sox1 or 3, however, loss-of-function studies
showed that both Sox2 and Sox3 require endogenous levels of Oct91
to induce neural tissue and therefore, partner with Oct91 to activate
early neural gene transcription. One possible explanation for the
discrepancy between the gain- and loss-of-function data is that Sox3
requires different partner proteins at different points in development.
Early in development, high levels of Oct91 interfere with the
interaction of Sox3 and a partner/co-activator. Later in development
Oct91 is required for Sox3 to activate expression. In toto, these data
indicate that while Oct91 is involved in the same pathway as Sox2 and
Sox3, Sox1 is outside the purview of Oct91 and induces neural tissue
with limited input from Oct91.
Precise levels of SoxB1s and Oct91 are necessary for proper neural
development
Our data indicate that the expression of SoxB1 target genes and
therefore SoxB1 protein function is dependent on the level of protein.
For example, overexpression of Sox2 induces expression of sox1 but
this level of sox1 is not sufﬁcient to induce sox3 expression, which is
upregulated in response to Sox1 overexpression. Additionally, both
Sox3 and Oct91 are expressed in uninjected ectodermal explants, but
are insufﬁcient to repress epidermal formation or induce neural tissue
formation in explants, even though they are capable of doing so when
overexpressed. Their functional dependence on expression level is
supported by the role of SoxB1 proteins levels in human diseases. For
example, mutation of a single allele of Sox2 is sufﬁcient to cause
severe eye, urogenital, and esophageal defects and seizures (Fantes
et al., 2003; Ferri et al., 2004; Williamson et al., 2006), whereas high
levels of Sox2 are found in a range of brain tumors (Kong et al., 2008;
Phi et al., 2008). Both high and low levels of Sox3 can deleteriously
affect normal brain function and physiology such as mental
retardation, growth hormone deﬁciencies and seizures (Bowl et al.,
2005; Hamel et al., 1996; Hol et al., 2000; Laumonnier et al., 2002;
Rousseau et al., 1991; Solomon et al., 2004; Stevanović et al., 1993;
Woods et al., 2005). Haploinsufﬁciency is a common trait within the
Sox family where one mutated allele of Sox8–10 can cause sex
reversal or hearing loss and megacolon (Bondurand et al., 2007;
Foster et al., 1994; Koopman, 2005; Pingault et al., 1998;Wagner et al.,
1994). Together these reports indicate that the levels of one Sox
protein may alter other Sox proteins and that normal brain function is
sensitive to precise levels of the Sox family proteins even when brain
morphology appears normal.
In conclusion, the SoxB1s and Oct91 can override BMP signaling in
the ectoderm to induce neural tissue, which parallels their ability to
induce iPS cells from mammalian cell lines (Ichida et al., 2009;
Takahashi and Yamanaka, 2006). Furthermore, just as Sox2 and Oct4
together regulate pluripotency in mammalian embryonic stem cells,
Oct91 cooperates with Sox2 to maintain neural progenitor marker
expression in Xenopus. The SoxB1s may have overlapping functions
but they are not strictly redundant as they have different roles in
maintaining progenitor identity. They reach the same endpoint,
progenitor maintenance, via different mechanisms.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.12.013.
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